Fintel reports that on May 12, 2026, Stephens & Co. initiated coverage of Palvella Therapeutics (NasdaqCM:PVLA) with a Overweight recommendation.
Analyst Price Forecast Suggests 91.68% Upside
As of April 28, 2026, the average one-year price target for Palvella Therapeutics is $234.03/share. The forecasts range from a low of $207.05 to a high of $283.50. The average price target represents an increase of 91.68% from its latest reported closing price of $122.09 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Palvella Therapeutics is 0MM. The projected annual non-GAAP EPS is -0.32.
What is the Fund Sentiment?
There are 173 funds or institutions reporting positions in Palvella Therapeutics. This is an decrease of 4 owner(s) or 2.26% in the last quarter. Average portfolio weight of all funds dedicated to PVLA is 0.25%, an increase of 72.89%. Total shares owned by institutions increased in the last three months by 26.20% to 11,469K shares. 
The put/call ratio of PVLA is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
Suvretta Capital Management holds 892K shares representing 6.23% ownership of the company. In its prior filing, the firm reported owning 822K shares , representing an increase of 7.84%. The firm increased its portfolio allocation in PVLA by 44.99% over the last quarter.
Bvf holds 879K shares representing 6.14% ownership of the company. In its prior filing, the firm reported owning 1,161K shares , representing a decrease of 32.11%. The firm increased its portfolio allocation in PVLA by 4.95% over the last quarter.
Frazier Life Sciences Management holds 722K shares representing 5.05% ownership of the company. No change in the last quarter.
First Light Asset Management holds 709K shares representing 4.95% ownership of the company. In its prior filing, the firm reported owning 542K shares , representing an increase of 23.63%. The firm increased its portfolio allocation in PVLA by 77.32% over the last quarter.
Jennison Associates holds 641K shares representing 4.48% ownership of the company. In its prior filing, the firm reported owning 387K shares , representing an increase of 39.51%. The firm increased its portfolio allocation in PVLA by 20.81% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
